Codex DNA, Inc. Stock News

Codex DNA Inc (DNAY) shares closed today 14.4% lower than it did at the end of yesterday. The stock is currently down 65.9% year-to-date, down 65.9% over the past 12 months, and down 65.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $7.79 and as low as $6.22 this week.Shares closed 75.4% below its 52-week high and 1.4% above its 52-week low.Trading volume this week was 41.2% higher than the 10-day average and 148.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Codex DNA Inc (DNAY) shares closed today at 1.4% above its 52 week low of $6.22, giving the company a market cap of $184M. The stock is currently down 65.9% year-to-date, down 65.9% over the past 12 months, and down 65.9% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1.2%. Trading Activity Trading volume this week was 150.1% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Codex DNA Inc (DNAY) shares closed today 14.4% lower than it did at the end of yesterday. The stock is currently down 65.9% year-to-date, down 65.9% over the past 12 months, and down 65.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $7.79 and as low as $6.22 this week.Shares closed 75.4% below its 52-week high and 1.4% above its 52-week low.Trading volume this week was 62.1% higher than the 10-day average and 150.1% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Codex DNA (NASDAQ:DNAY) and Bruker (NASDAQ:BRKR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Profitability This table compares Codex DNA and Brukers net margins, return on equity and return on assets. []

Codex DNA’s (NASDAQ:DNAY) lock-up period will end on Wednesday, December 15th. Codex DNA had issued 6,666,665 shares in its initial public offering on June 18th. The total size of the offering was $106,666,640 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders will be eligible […]

Codex DNAs (NASDAQ:DNAY) lock-up period will expire on Wednesday, December 15th. Codex DNA had issued 6,666,665 shares in its public offering on June 18th. The total size of the offering was $106,666,640 based on an initial share price of $16.00. After the expiration of the companys lock-up period, restrictions preventing major shareholders and company insiders []

Codex DNA Inc (DNAY) shares closed today at 1.9% above its 52 week low of $6.48, giving the company a market cap of $199M. The stock is currently down 63.2% year-to-date, down 63.2% over the past 12 months, and down 63.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 35.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the commercial launch of its BioXp mRNA synthesis kits with CleanCap® Reagent AG, a proprietary mRNA capping technology from TriLink BioTechnologies, part of Maravai LifeSciences (NASDAQ: MRVI). These new automation kits will allow users to generate large yields of high-quality, capped mRNA to accelerate the discovery and development of mRNA-based vaccines and therapeutics.

San Diego, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY ), a pioneer in automated benchtop synthetic biology systems, and RNAimmune, a leading biotech company with expertise in messenger RNA (mRNA) design and delivery technologies, today announced the initiation of work under a collaboration to optimize the development and validation of Codex DNA''s future mRNA synthesis kits. Over the past two years, mRNA has emerged as a promising platform for the development of vaccines and therapeutics. However, robust and reliable production of mRNA remains challenging, resulting in significantly increased timelines during the critical phases of discovery and development that call for rapid iterations of construct designs for optimization. Codex DNA addresses these challenges by empowering researchers with an automated solution for their mRNA synthesis needs. Automated synthesis of mRNA from a digital sequence input reduces the build process by weeks and shrinks the iterative cycle time.

Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company's chief ex

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its third quarter 2021 fina

Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021

Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q2 2021 Results - Earnings Call Transcript

SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended Ju